tirzepatide for metabolic dysfunction In the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary Frontiers | Tirzepatide against obesity

Tirzepatide is a novel dual agonist that targets both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor (13, 14)

Blood pressure dynamics: Despite weight loss, glucagon activation can create more complex blood pressure fluctuations early in treatment

Avoid overly acidic foods

Lean protein What to eat: Skinless poultry (e.g

McGowan said fewer than one in five commercial insurers offers coverage for brand-name GLP-1 medications, "making them unobtainable for most individuals." GET FOX BUSINESS ON THE GO BY CLICKING HERE Lilly has been urging "employers, insurers, and the government to recognize that obesity is a chronic disease and to increase coverage of medicines to treat it." In the meantime, eligible patients with commercial insurance coverage can get Zepbound for as low as $25 a month, Lily said